Filing Details
- Accession Number:
- 0001127602-21-013342
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-04-06 16:13:49
- Reporting Period:
- 2021-04-05
- Accepted Time:
- 2021-04-06 16:13:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1682852 | Moderna Inc. | MRNA | Biological Products, (No Disgnostic Substances) (2836) | 813467528 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1690927 | Zvi Tal Zaks | C/O Moderna, Inc. 200 Technology Square Cambridge MA 02139 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-04-05 | 5,000 | $12.21 | 5,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-04-05 | 610 | $127.76 | 1,964 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-04-05 | 814 | $128.65 | 1,150 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-04-05 | 2,426 | $129.96 | 2,574 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-04-05 | 1,150 | $130.95 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-04-05 | 5,000 | $0.00 | 5,000 | $12.21 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 161,282 | 2027-10-03 | No | 4 | M | Direct |
Footnotes
- The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.21 to $128.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.33 to $129.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.47 to $130.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.58 to $131.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).
Billionaire Hedge Funds
